219 results about "Prostate-specific antigen" patented technology

The invention provides isolated PSMA binding peptides, as well as pharmaceutical compositions thereof. Also provided are diagnostic and therapeutic methods utilizing the PSMA binding peptides, as well as methods for identifying further PSMA binding peptides.

The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.

A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

The invention described herein provides methods, compositions, kits, and systems for the sensitive detection of prostate specific antigen. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of prostate specific antigen.

The present invention is directed to sensitive and specific methods and kits for the detection of prostate cancer in a patient. The invention uses RT-PCR to detect the expression or change in expression of PSA in epithelial cells enriched from whole blood. The methods and kits on the invention represent a a significant improvement over previous methods of CaP diagnosis. According to one embodiment, prostate epithelial cells are isolated from blood and the RNA subjected to RT-PCR. The resulting cDNA is subjected to traditional PCR amplification with primers able to distinguish between the genomic copy of the gene and the cDNA copy resulting from CaP gene expression. This method provides an assay which is more sensitive, specific and reproducible as compared to conventional methods. Results disclosed herein demonstrate a correlation between the presence of PSA-expressing prostate epithelial cells with cancer recurrence which provides a diagnostic tool for the early detection of prostate disease.

Method of monitoring or diagnosing disease conditions, including disease of the prostate, that involve measuring a combination of tumor markers and at least one component of the IGF axis. The invention is exemplified with prostate cancer and benign prostatic hyperplasia, the tumor marker prostate specific antigen, and the insulin-like growth factors and their binding proteins.

An object of the present invention is to provide an immunoassay of PSA using an agglutination accelerator, which has an agglutination accelerating effect equal to or stronger than the known agglutination accelerator; hardly generates non-specific turbidity; and hardly generates salting out even in a solution with a high salt concentration. The present invention relates to an immunoassay of a prostate-specific antigen comprising performing an antigen-antibody reaction in the presence of a polymer having a monomer unit derived from a monomer represented by the following general formula [2]: (wherein R<1>-R<3 >are each independently a hydrogen atom or an alkyl group optionally having a hydroxyl group; R<4 >is an alkylene group; R<5 >is an alkylene group optionally having a substituent and optionally having an oxygen atom in a chain; R<6 >is a hydrogen atom or a methyl group, and X is an oxygen atom or a -NH- group), and a kit of reagent for an immunoassay comprising a reagent containing an agglutination accelerator for the immunoassay.

The invention relates to a nanotechnology-based trace protein detection method, which combines enzyme-linked immunosorbent assay technology, tyramine signal amplification technology and the aggregation phenomenon of gold nanoparticles modified by different biological molecules, so an experimental method used for detecting trace proteins such as prostate specific antigen (PSA) and the like is established. The method comprises the following steps of: fixing an antibody aiming at the protein to be detected (such as the PSA) on the surface of a substrate; incubating another antibody with horseradish peroxidase (HRP) activity of the protein to be detected (such as the PSA) after capturing the protein to be detected in a sample, wherein the HRP catalyzes biotin-tyramide to generate biotin deposition under certain conditions; further amplifying a signal by using the aggregation phenomenon of the gold nanoparticles modified by biotin-labeled DNA and the gold nanoparticles modified by streptavidin; performing silver staining; and performing data analysis on an experimental result by using software. The method has the advantages of extremely low detection limit, wider detection range, capacity of detecting the antigen in a rabbit serum with complex compositions, and important application prospect.

Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

The disclosure provides for methods to determine prognosis, aggressiveness, and progression of prostate cancer with the ability to differentiate between aggressive and non-aggressive prostate cancer. The method utilizes the differential enzymatic activity in patient samples, for example of enzymatically active prostate specific antigen (PSA) activity, in order to determine the aggressiveness and prognosis of prostate cancer, and monitor the progression of prostate cancer therapy. The invention also encompasses assay platforms (e.g., optical or electrochemical) that specifically detect PSA-triggered peptide cleavage events.

The invention discloses a quantitative detection method for pyrethriods pesticides in fresh tea. The quantitative detection method is characterized by comprising the following steps: ultrasonically extracting a fresh tea sample by an acetonitrile solution containing 1% of acetic acid in percentage by volume, then purifying by using an appropriate amount of mixed filler of PSA (Prostate Specific Antigen), C18 and GCB, carrying out nitrogen blowing to concentrate liquid supernatant to be nearly dry, dissolving with normal hexane and making up to volume, increasing programmed temperature and separating by using an HP-5 quartz capillary column, carrying out GC/muECD, and finally quantifying by using a matrix external standard method. Through confirmation by test, the method is wide in linear range; the technical indexes such as detection sensitivity, accuracy and precision meet the requirements of analysis of residues; the pretreatment operation is simple, convenient and quick; through the method, a reliable manner is provided for analysis and research for detecting the residues of the pyrethriods pesticides in the fresh tea.

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.

This invention relates to three kinds of monoclonal antibody of prostate specific antigen(PSA), and corresponding hybridoma cell strain. The preservation number respectively are: CCTCC-C200620, CCTCC-C200621 and CCTCC-C200622. The detection range of this monoclonal antibody can reach 0 to 2048ng/mL, possess feature of sensitivity, idiosyncratic and low cost. The invention has important application prospects at cytobiology, biomacromolecule detection and medicine clinical diagnosis etc.

The invention relates to a preparation method of a prostate tumor marker immunosensor. The preparation method comprises the following steps: (1) dissolving silver-hybridized NH2-MCM-48 into a phosphate buffered solution, uniformly dispersing in an ultrasonic mode, further adding a prostate specific antigen second antibody, oscillating at the temperature of 4 DEG C, centrifuging to remove the supernate to obtain a second antibody marker Ag@NH2-MCM-48/Ab2; (2) firstly, modifying the surface of a glassy carbon electrode as a working electrode by using an amino graphene-ferrocenecarboxaldehyde composite material solution, subsequently modifying by using glutaraldehyde, further modifying by using a prostate specific antigen-anti-solution, dropping a bovine serum albumin solution, continuously modifying prostate specific antigen, and finally modifying Ag@NH2-MCM-48/Ab1 so as to obtain the prostate tumor marker immunosensor. The immunosensor prepared by using the preparation method is applied to measurement on the prostate specific antigen, and is high in sensitivity and good in specificity.